BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has announced the placement of 15 new Deep Transcranial Magnetic Stimulation (Deep TMS™) systems in Taiwan and South Korea. This expansion marks a significant step in the company's penetration of the East Asian market.
CEO Hadar Levy highlighted the strategic importance of these countries in BrainsWay's international growth strategy, noting that the new orders demonstrate the company's ongoing commercial success in the region. The BrainsWay team, along with their international distribution partners, is focused on expanding global access to their innovative Deep TMS platform for both patients and healthcare providers.
BrainsWay (NASDAQ & TASE: BWAY), leader nei trattamenti di neurostimolazione non invasiva per i disturbi mentali, ha annunciato l'installazione di 15 nuovi sistemi di Stimolazione Magnetica Transcranica Profonda (Deep TMS™) a Taiwan e in Corea del Sud. Questa espansione rappresenta un passo significativo nella penetrazione dell'azienda nel mercato dell'Asia orientale.
Il CEO Hadar Levy ha evidenziato l'importanza strategica di questi paesi nella strategia di crescita internazionale di BrainsWay, sottolineando che i nuovi ordini dimostrano il continuo successo commerciale dell'azienda nella regione. Il team di BrainsWay, insieme ai propri partner di distribuzione internazionali, si concentra sull'ampliamento dell'accesso globale alla loro innovativa piattaforma Deep TMS sia per i pazienti che per i fornitori di servizi sanitari.
BrainsWay (NASDAQ & TASE: BWAY), líder en tratamientos de neuroestimulación no invasiva para trastornos de salud mental, ha anunciado la colocación de 15 nuevos sistemas de Estimulación Magnética Transcraneal Profunda (Deep TMS™) en Taiwán y Corea del Sur. Esta expansión marca un paso significativo en la penetración de la empresa en el mercado de Asia Oriental.
El CEO Hadar Levy destacó la importancia estratégica de estos países en la estrategia de crecimiento internacional de BrainsWay, señalando que los nuevos pedidos demuestran el continuo éxito comercial de la empresa en la región. El equipo de BrainsWay, junto con sus socios de distribución internacional, está enfocado en ampliar el acceso global a su innovadora plataforma Deep TMS tanto para pacientes como para proveedores de atención médica.
BrainsWay (NASDAQ & TASE: BWAY), 정신 건강 장애를 위한 비침습적 신경 자극 치료의 선두주자가, 대만과 한국에 15개의 새로운 깊은 경두개 자기 자극(Deep TMS™) 시스템을 배치했다고 발표했습니다. 이번 확장은 회사의 동아시아 시장 침투에 있어 중요한 진전을 의미합니다.
CEO 하다르 레비는 이러한 국가들이 BrainsWay의 국제 성장 전략에서 전략적으로 중요하다고 강조하며, 새로운 주문이 이 지역에서 회사의 지속적인 상업적 성공을 보여준다고 언급했습니다. BrainsWay 팀과 그들의 국제 유통 파트너들은 환자와 의료 제공자를 위한 혁신적인 Deep TMS 플랫폼에 대한 글로벌 접근성을 확대하는 데 집중하고 있습니다.
BrainsWay (NASDAQ & TASE: BWAY), leader dans le traitement de neurostimulation non invasive pour les troubles de la santé mentale, a annoncé la mise en place de 15 nouveaux systèmes de Stimulation Magnétique Transcrânienne Profonde (Deep TMS™) à Taïwan et en Corée du Sud. Cette expansion représente une étape importante dans la pénétration de l’entreprise sur le marché de l’Asie de l’Est.
Le PDG Hadar Levy a souligné l'importance stratégique de ces pays dans la stratégie de croissance internationale de BrainsWay, notant que les nouvelles commandes prouvent le succès commercial continu de l’entreprise dans la région. L'équipe de BrainsWay, avec leurs partenaires de distribution internationaux, est axée sur l'extension de l'accès global à leur plateforme innovante Deep TMS pour les patients et les fournisseurs de soins de santé.
BrainsWay (NASDAQ & TASE: BWAY), ein führendes Unternehmen für nicht-invasive Neurostimulationsbehandlungen bei psychischen Störungen, hat die Platzierung von 15 neuen Systemen für die Tiefe Transkranielle Magnetstimulation (Deep TMS™) in Taiwan und Südkorea angekündigt. Diese Expansion stellt einen bedeutenden Schritt in der Marktdurchdringung des Unternehmens im ostasiatischen Raum dar.
CEO Hadar Levy hob die strategische Bedeutung dieser Länder für die internationale Wachstumsstrategie von BrainsWay hervor und bemerkte, dass die neuen Bestellungen den anhaltenden kommerziellen Erfolg des Unternehmens in der Region verdeutlichen. Das Team von BrainsWay konzentriert sich gemeinsam mit seinen internationalen Vertriebspartnern auf die Erweiterung des globalen Zugangs zu ihrer innovativen Deep TMS-Plattform für sowohl Patienten als auch Gesundheitsdienstleister.
- Placement of 15 new Deep TMS systems in Taiwan and South Korea
- Expansion in strategically important East Asian market
- Continued commercial success and growing demand in the region
- None.
Insights
The placement of 15 additional Deep TMS™ systems in Taiwan and South Korea represents a significant expansion for BrainsWay in the East Asian market. This move demonstrates growing acceptance and demand for non-invasive neurostimulation treatments in the region. The Deep TMS technology, which is used to treat mental health disorders, could potentially address a large patient population in these countries.
From an investor perspective, this expansion is positive for several reasons:
- It diversifies BrainsWay's revenue streams geographically
- It indicates market validation of their technology in new territories
- It suggests potential for further growth in the East Asian market
However, it's important to note that while 15 systems is a notable increase, the overall impact on BrainsWay's financials may be in the short term given the company's
The expansion into Taiwan and South Korea aligns with BrainsWay's international growth strategy and could be a stepping stone for broader penetration in East Asia. These markets are particularly attractive due to:
- High population density
- Increasing mental health awareness
- Growing healthcare expenditure
The company's ability to secure multiple system placements suggests a positive reception from healthcare providers. This could lead to increased brand recognition and potential word-of-mouth marketing within the medical community. However, investors should consider:
- The pace of adoption and utilization rates of these systems
- Potential regulatory challenges in new markets
- Competition from local and international medical device companies
While this news is encouraging, it's important to monitor future announcements regarding system usage, patient outcomes and revenue generation from these placements to fully assess the long-term impact on BrainsWay's market position and financial performance.
BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of its Deep Transcranial Magnetic Stimulation (Deep TMS™) platform in East Asia through the placement of 15 new systems in Taiwan and South Korea.
“The recent orders for 15 additional Deep TMS systems to be used by mental health centers in Taiwan and South Korea are indicative of the continued commercial success we are experiencing in penetrating this strategically important region. These countries each play an important role in our international growth strategy, and we are pleased to report the expanding demand from the East Asia region,” said Hadar Levy, BrainsWay’s Chief Executive Officer. “The BrainsWay team and our international distribution partners continue to focus on expanding access to our innovative Deep TMS platform among patients and healthcare providers globally.”
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements include, among others, statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the anticipated use of proceeds therefrom, the ability of the Company to obtain shareholder approval, and the exercise of the Warrants prior to their expiration, and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: market and other conditions, inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
FAQ
How many new Deep TMS systems has BrainsWay placed in East Asia?
What is the significance of BrainsWay's expansion in East Asia for the company?
What is BrainsWay's stock symbol?
What is BrainsWay's main product?
